BioNotebook: Puma CEO sees sale as option, Tesaro drops, Can-Fite gains on study results
This article was originally published in Scrip
'Tis the season to dump good and bad news just before the holidays. Despite the upbeat headline in the company's press release, Tesaro reported mixed results for a late-stage experimental drug. Can-Fite BioPharma had better news. And Puma Biotechnology's CEO, a man with a love of big cat names, vows to do what's right for his shareholders.
You may also be interested in...
Using Baxter’s Advate drug as a preventative therapy helped significantly reduce bleeding incidents in a yearlong study.
Mylan CEO Heather Bresch said she is looking to do a sizable deal that helps the US generic and specialty drug maker better compete in a consolidating field of rivals.
Biogen Idec CEO George Scangos is frank about his ambitions to dominate the market for hemophilia therapies, an opportunity he compares to the big biotech’s lead treating multiple sclerosis.